Adverse Drug Reaction

Celecoxib inhibits interleukin-12 alpha beta and beta(2) folding and secretion

Published in Cardiovascular Week, June 12th, 2006

According to a study from North Ireland, celecoxib (CE) inhibits interleukin-12 (IL-12) alpha beta and beta(2) folding and secretion by a novel cyclooxygenase 2 (COX2)-independent mechanism involving chaperones of the endoplasmic reticulum (ER).

"CE is a nonsteroidal anti-inflammatory drug (NSAID) that is a specific inhibitor of COX2. It is indicated for a variety of chronic inflammatory conditions, including rheumatoid arthritis. Over the last few years, adverse cardiovascular effects and increased risk for heart attacks have been associated with this drug. In addition, evidence is emerging for COX2-independent molecular targets," wrote I. Alloza and colleagues, Queens...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Week

Source: Cardiovascular Week (2006-06-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry